Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Accounts Payables (2023 - 2025)

Historic Accounts Payables for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to $6.1 million.

  • Immunome's Accounts Payables rose 7473.0% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 million, marking a year-over-year increase of 7473.0%. This contributed to the annual value of $14.2 million for FY2024, which is 32854.12% up from last year.
  • Latest data reveals that Immunome reported Accounts Payables of $6.1 million as of Q3 2025, which was up 7473.0% from $4.7 million recorded in Q2 2025.
  • Over the past 5 years, Immunome's Accounts Payables peaked at $14.2 million during Q4 2024, and registered a low of $2.8 million during Q3 2023.
  • Moreover, its 3-year median value for Accounts Payables was $4.7 million (2025), whereas its average is $5.9 million.
  • As far as peak fluctuations go, Immunome's Accounts Payables soared by 32854.12% in 2024, and later crashed by 3387.26% in 2025.
  • Quarter analysis of 3 years shows Immunome's Accounts Payables stood at $3.3 million in 2023, then soared by 328.54% to $14.2 million in 2024, then plummeted by 56.68% to $6.1 million in 2025.
  • Its Accounts Payables was $6.1 million in Q3 2025, compared to $4.7 million in Q2 2025 and $9.1 million in Q1 2025.